Navigation Links
Genzyme Reports Strong Second-Quarter Growth
Date:7/23/2008

registered trademarks of and Mozobil(TM) and Synvisc-ONE(TM) are unregistered trademarks of Genzyme or its subsidiaries. Aldurazyme(R) is a registered trademark of BioMarin/Genzyme LLC. All rights reserved.

About Genzyme

One of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Since 1981, the company has grown from a small start-up to a diversified enterprise with more than 10,000 employees in locations spanning the globe and 2007 revenues of $3.8 billion. In 2007, Genzyme was chosen to receive the National Medal of Technology, the highest honor awarded by the President of the United States for technological innovation.

With many established products and services helping patients in nearly 90 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant, and diagnostic testing. Genzyme's commitment to innovation continues today with a substantial development program focused on these fields, as well as immune disease, cardiovascular disease, and other areas of unmet medical need.

Conference Call Information

Genzyme will host a conference call today at 11:00 a.m. Eastern to discuss results for the second quarter of 2008. To participate in the call, please dial 1-773-799-3828 and refer to passcode "Genzyme." A replay of this call will be available by dialing 402-998-1342. This call will also be Webcast live on the investor events section of http://www.genzyme.com. Replays of the call and the Webcast will be available until midnight July 30, 2008.

Upcoming Events

Genzyme will host a conference call on October 22, 2008 at 11: 00 a.m. Eastern to discuss financial results for the third quarter of 200
'/>"/>

SOURCE Genzyme Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related biology technology :

1. Novel Angiogenic Drugs, Including a Future Blockbuster from Genzyme, Could Revolutionize Treatment of Peripheral Arterial Disease
2. Genzyme Begins Major Expansion of Boston Manufacturing Facility
3. Genzyme Affirms Purchase Price for Bioenvision at $5.60 Per Outstanding Share
4. Genzyme Receives Approval to Market Elaprase(R) in Japan
5. Genzyme Recognized by Scientists as a Top Employer
6. Genzyme to Participate in FDA Advisory Committee Meeting on the Use of Phosphate Binders in Chronic Kidney Disease
7. FDA Approves Genzymes Renvela(TM) for Dialysis Patients
8. Genzyme Launches Cholestagel(R) in Europe
9. BioVex Appoints Genzyme Executive, Jan van Heek, as Chairman of the Board of Directors
10. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
11. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... DUBLIN , Sept. 18, 2014 ... the "Global Companion Diagnostics (Polymerase Chain Reaction, In-situ ... report to their offering. The ... a CAGR of 22.7% from 2014 to 2019. Factors ... treatment, growing adoption of companion diagnostics by the pharmaceutical ...
(Date:9/18/2014)... -- U.S. biotech company Kultevat has strengthened its ... developed by the Donald Danforth Plant Science Center ... applications in production of natural rubber in Taraxicum ... under the direction of Roger Beachy , Ph.D., ... the Danforth Plant Science Center, and is used to ...
(Date:9/18/2014)... Sept. 18, 2014  Neogen Corporation (Nasdaq: ... a strategic agreement with Merck Animal Health to market ... The Igenity Dairy Heifer Program consists of genomic ... the genetic potential of replacement dairy heifers. The genomic ... born, and is an excellent tool in the decision-making ...
(Date:9/18/2014)... Pennsylvanie, 18 septembre 2014 Mapi, ... en 1974, a été depuis 40 ans ... évaluations cliniques traditionnelles par des évaluations recentrées ... sur les impacts économiques des traitements. ... A cours d,une récente conférence ...
Breaking Biology Technology:Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 2Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 3Kultevat obtains license of gene switch technology 2Merck Animal Health to market Neogen's dairy genomic program 21974 - 2014 - Mapi fĂȘte ses 40 ans 2
... toward large-scale production -SWIFTWATER, Pa. and LYON, France, May ... sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY ... A(H1N1) seed virus, enabling the world,s leading manufacturer of ... A(H1N1) vaccine. The emergence of a new influenza A(H1N1) ...
... CA, May 27, 2009 Senomyx, Inc. (Nasdaq: ... proprietary technologies to discover and develop novel flavor ingredients ... today the appointment of David L. Linemeyer, Ph.D., to ... than 20 years of experience in directing biology research ...
... atherosclerosis vaccine,development program by AFFiRiS AG is receiving ... project is being carried out in,cooperation with German ... is to increase the amount of "good" high ... reduce the occurrence of,harmful fatty deposits in the ...
Cached Biology Technology:Sanofi Pasteur Receives Seed Virus to Produce New Influenza A(H1N1) Vaccine 2Sanofi Pasteur Receives Seed Virus to Produce New Influenza A(H1N1) Vaccine 3SENOMYX ANNOUNCES APPOINTMENT OF DAVID L. LINEMEYER, PH.D., AS VICE PRESIDENT, BIOLOGY 2SENOMYX ANNOUNCES APPOINTMENT OF DAVID L. LINEMEYER, PH.D., AS VICE PRESIDENT, BIOLOGY 3AFFiRiS AG: Atherosclerosis Vaccine Development Receives EU Support 2AFFiRiS AG: Atherosclerosis Vaccine Development Receives EU Support 3
(Date:9/18/2014)... New research into the Crimean-Congo hemorrhagic fever virus ... disease in humans similar to that caused by Ebolavirus, ... This discovery has the potential to lead to novel ... , The research, reported in a paper published today ... by scientists at the Texas Biomedical Research Institute and ...
(Date:9/18/2014)... starts a "frequent flyers" program, fruit flies surely would ... has hosted increasing numbers of fruit fly research studies. ... in April, and another is scheduled launch to the ... launch in December. , Fruit flies are biomedical research ... space. Model organisms can reveal the basis for health ...
(Date:9/18/2014)... creatively manipulate spoken language is unique to humans. "The ... years of human evolution to make this possible are ... we now have," says Wolfgang Enard, Professor of Anthropology ... understand the molecular biological basis of language Enard has ... his latest study, undertaken in collaboration with scientists at ...
Breaking Biology News(10 mins):Research milestone in CCHF virus could help identify new treatments 2Buzzing with activity: Fruit flies orbit Earth for science 2Buzzing with activity: Fruit flies orbit Earth for science 3Buzzing with activity: Fruit flies orbit Earth for science 4Language evolution: Quicker on the uptake 2Language evolution: Quicker on the uptake 3
... ants it's a way of life! Scientists at the University ... how to visually judge the height of horizontal barriers so ... Tobias Seidl will be presenting his latest research findings at ... Tuesday 4th April. , Desert ants generally scurry around at ...
... pups whose blubber falls below average levels may be at ... they get enough fat in their diets later on, according ... and presented at Experimental Biology 2006. , The study found ... the wild continued to gain weight and grow regardless of ...
... recently discovered cytokine to neural stem cells derived from ... Neurosurgical Institute have developed a tool to track and ... against their return. , Results of an animal study ... Cancer Research, and the researchers are now applying to ...
Cached Biology News:Alaska seal pup diet may hold key to decline of population 2Alaska seal pup diet may hold key to decline of population 3Alaska seal pup diet may hold key to decline of population 4Marrow-derived stem cells deliver new cytokine to kill brain tumor cells, offer protection 2Marrow-derived stem cells deliver new cytokine to kill brain tumor cells, offer protection 3
Mouse polyclonal antibody to ALS2CR8 - amyotrophic lateral sclerosis 2 (juvenile) chromosome region, candidate 8...
...
Mouse monoclonal [CAT-2] to Chloramphenicol Acetyltransferase...
Recommended fro Western blotting application...
Biology Products: